Understanding Drug-Induced Acneiform Rash
Trusted resources for patients and healthcare professionals about skin rash caused by EGFR inhibitors and daraxonrasib (Rasonque).
Many effective cancer treatments , including EGFR inhibitors such as cetuximab (Erbitux) and panitumumab (Vectibix) , cause an acne-like skin rash in the majority of patients. This drug-induced acneiform rash most often appears on the face, scalp, chest, and back, and can be itchy, painful, and distressing. For some patients it becomes severe enough to interrupt cancer treatment. The resources below, from leading cancer centers and professional societies, explain why this rash happens and how it can be managed. Lutris Pharma is developing LUT014, an investigational topical gel designed to control this rash without compromising the benefit of cancer therapy.
For Patients
Guides and leaflets for people receiving EGFR inhibitor therapy or daraxonrasib (Rasonque), and their caregivers.
Skin Care During Treatment With EGFR Inhibitors
Practical skin-care guidance for patients taking EGFR inhibitors such as cetuximab, panitumumab, and erlotinib , gentle routines, sun protection, and when to call your care team.
Rashes and Skin Changes
A comprehensive patient guide to rashes caused by cancer treatment: what causes them, common types, warning signs, and tips for managing skin changes day to day.
Targeted Drug Therapy Side Effects
Explains why targeted cancer therapies , including EGFR inhibitors , affect healthy skin, hair, and nail cells, and what patients can expect during treatment.
Daraxonrasib: Patient Education
Patient and caregiver information about daraxonrasib (Rasonque), including skin reactions, other possible side effects, and when to contact the cancer care team.
How to Deal with Targeted Therapy-Related Skin Rashes
A dermatologist-written Q&A on why about 80% of patients on EGFR inhibitors develop an acne-like rash, how it can be prevented, and how to stay on treatment.
Acne-like Rash in Cancer Patients , Information Leaflet for Patients
A patient leaflet explaining what the acne-like rash is, why EGFR, MEK, and mTOR inhibitors cause it, and the best ways to prevent and treat it.
Understanding Rash During Rasonque Treatment
The manufacturer's patient guide to recognizing rash during daraxonrasib treatment, with visual examples and practical advice on skin care and managing skin reactions.
Managing Erbitux & Vectibix Skin Side Effects
Patient-friendly tips for managing skin reactions from the two most common anti-EGFR antibodies , sun protection, gentle skincare, and signs that need medical attention.
Skin Side Effects: Tips and Tricks
A plain-language guide to why anti-EGFR drugs affect the skin, how to manage symptoms before and during treatment, and how to cope with the emotional impact of a visible rash.
Rasonque Side Effects: What to Expect and How to Manage Them
A patient-friendly overview of daraxonrasib (Rasonque) side effects, including acne-like rash, prevention strategies, and discussing symptoms with the care team.
Understanding and Managing Treatment-Related Acneiform Rash
A patient education sheet on what acneiform rash is, who is at risk, and practical do's and don'ts , including why the rash can signal that cancer treatment is working.
For Healthcare Professionals
Accessible overviews of the condition and its management for oncologists, nurses, and other non-dermatologists.
Cutaneous Adverse Events of Molecularly Targeted Therapy
The clinical reference most non-dermatologists use , a regularly updated overview of skin toxicities from EGFR, BRAF, and MEK inhibitors and their impact on dosing and quality of life.
Recommended Prophylaxis for Rasonque
The manufacturer's guidance for healthcare professionals on preventive skin care, topical corticosteroids, and antibiotics to reduce dermatologic reactions during daraxonrasib therapy.
Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
A readable open-access review of how EGFR inhibitor skin toxicity presents, how it is managed, and the observed correlation between rash and tumor response.
Managing Rash and Stomatitis With Daraxonrasib in Pancreatic Cancer
An oncology nursing overview of proactive management of rash and mouth inflammation during daraxonrasib treatment, including supportive care and coordination with the clinical team.
Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights
A concise review of the epidemiology, pathogenesis, and treatment of EGFR inhibitor-induced acneiform rash, accessible to oncologists and informed patients.
These resources are produced by external organizations and are provided for general information only. They are not medical advice. Always talk to your cancer care team before making any change to your treatment or skin-care routine.